Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 ,inter alia, to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement titled - Intimation about 32nd Annual General Meeting of the Company and Record Date for Dividend. Strides Pharma Science Ltd - 532531 - Intimation About Record Date For The Purpose Of Dividend For FY23.
Intimation about Record Date for the purpose of Dividend for FY23. Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 17, 2023 for Pronomz Ventures LLP & Padmakumar Karunakaran Pillai Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC to Satish Gandhi Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC - Sangeetha Dinkar Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 30,150 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under the Strides ESOP 2016.
Strides Pharma sinks after subsidiary plans to divest manufacturing plant
The manufacturing unit has a potential for future expansion up to a further 20,000 litres of biologics drug substance manufacturing capacity. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
"Stelis Biopharma enters into a binding term sheet with Syngene International Limited to divest its Unit 3 multi-modal facility for a gross consideration of INR 7,020 million"